Literature DB >> 17384584

Hyperactive Ras in developmental disorders and cancer.

Suzanne Schubbert1, Kevin Shannon, Gideon Bollag.   

Abstract

Ras genes are the most common targets for somatic gain-of-function mutations in human cancer. Recently, germline mutations that affect components of the Ras-Raf-mitogen-activated and extracellular-signal regulated kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway were shown to cause several developmental disorders, including Noonan, Costello and cardio-facio-cutaneous syndromes. Many of these mutant alleles encode proteins with aberrant biochemical and functional properties. Here we will discuss the implications of germline mutations in the Ras-Raf-MEK-ERK pathway for understanding normal developmental processes and cancer pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17384584     DOI: 10.1038/nrc2109

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  630 in total

Review 1.  Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras.

Authors:  Anica Wandler; Kevin Shannon
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

2.  cPLA2 regulates the expression of type I interferons and intracellular immunity to Chlamydia trachomatis.

Authors:  Mark J Vignola; David F Kashatus; Gregory A Taylor; Christopher M Counter; Raphael H Valdivia
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

Review 3.  Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab.

Authors:  Bing-Bing Yang; Peggy Lum; Alin Chen; Rosalin Arends; Lorin Roskos; Brian Smith; Juan José Pérez Ruixo
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

4.  Preclinical efficacy of MEK inhibition in Nras-mutant AML.

Authors:  Michael R Burgess; Eugene Hwang; Ari J Firestone; Tannie Huang; Jin Xu; Johannes Zuber; Natacha Bohin; Tiffany Wen; Scott C Kogan; Kevin M Haigis; Deepak Sampath; Scott Lowe; Kevin Shannon; Qing Li
Journal:  Blood       Date:  2014-10-31       Impact factor: 22.113

5.  Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras.

Authors:  Jin Xu; Christian Hedberg; Frank J Dekker; Qing Li; Kevin M Haigis; Eugene Hwang; Herbert Waldmann; Kevin Shannon
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

6.  Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.

Authors:  Neerav Shukla; Nabahet Ameur; Ismail Yilmaz; Khedoudja Nafa; Chyau-Yueh Lau; Angela Marchetti; Laetitia Borsu; Frederic G Barr; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2011-12-05       Impact factor: 12.531

7.  Characterization of KRAS rearrangements in metastatic prostate cancer.

Authors:  Xiao-Song Wang; Sunita Shankar; Saravana M Dhanasekaran; Bushra Ateeq; Atsuo T Sasaki; Xiaojun Jing; Daniel Robinson; Qi Cao; John R Prensner; Anastasia K Yocum; Rui Wang; Daniel F Fries; Bo Han; Irfan A Asangani; Xuhong Cao; Yong Li; Gilbert S Omenn; Dorothee Pflueger; Anuradha Gopalan; Victor E Reuter; Emily Rose Kahoud; Lewis C Cantley; Mark A Rubin; Nallasivam Palanisamy; Sooryanarayana Varambally; Arul M Chinnaiyan
Journal:  Cancer Discov       Date:  2011-06-01       Impact factor: 39.397

8.  Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1-MAPK Interaction.

Authors:  Xin Jin; Yunqian Pan; Liguo Wang; Tao Ma; Lizhi Zhang; Amy H Tang; Daniel D Billadeau; Heshui Wu; Haojie Huang
Journal:  Cancer Res       Date:  2017-07-18       Impact factor: 12.701

9.  A genome-wide analysis of colorectal cancer in a child with Noonan syndrome.

Authors:  Rahul M Prasad; Rajen J Mody; George Myers; Melisa Mullins; Zaher Naji; James D Geiger
Journal:  Pediatr Blood Cancer       Date:  2018-07-24       Impact factor: 3.167

10.  Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.

Authors:  Gordon Chan; Demetrios Kalaitzidis; Tatiana Usenko; Jeffery L Kutok; Wentian Yang; M Golam Mohi; Benjamin G Neel
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.